On May 5, 2020 Immunophage, a Nanjing biotech, reported that it closed a $14 million Pre-A financing, led by Jinfang Hongrui Investment Management, to support its immune-regulating candidates for cancer, autoimmune and neurodegenerative indications (Press release, Nanjing Immunophage Biotech, MAY 5, 2020, View Source [SID1234557192]). The company’s lead cancer projects have dual or multiple anti-tumor properties that pair inhibitors of tumor growth with mechanisms that reverse the tumor’s immunosuppressive environment. IPG1094 inhibits tumor growth and the formation of target-mediated myeloid suppressor cells. IPG7236 inhibits tumor metastasis and tumor-related regulatory T cell infiltration. Immunophage’s R&D operations are in Shanghai’s Caohejing Pujiang High-Tech Park.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!